Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

Arcus Biosciences, at Citi's Biopharma conference, highlighted its late-stage pipeline, particularly the HIF-2 alpha inhibitor casdatifan, which it positions as "best-in-class" against Merck's belzutifan, citing superior efficacy and a more durable pharmacodynamic profile in a $10 billion market. Two Phase III programs for casdatifan in RCC are underway, with an October 6th investor event slated to release updated monotherapy data including PFS. Additional catalysts include upcoming OS data for its Fc-silent anti-TIGIT dom-zim at ESMO, derisking its STAR-221 Phase III, and the rapid, early completion of enrollment for its CD73 inhibitor quemli's Phase III in pancreatic cancer, with a readout expected within 12-18 months. This continuous flow of late-stage data and multiple Phase III readouts through 2027 marks a "transformational period" for Arcus across major competitive markets.

Analysis

Arcus Biosciences (RCUS) is positioning its late-stage pipeline for a series of major data readouts, with a primary focus on establishing its HIF-2 alpha inhibitor, casdatifan, as a best-in-class molecule in a market estimated at $10 billion. Management asserts clear clinical superiority over Merck's (MRK) competing drug, belzutifan, citing a dramatically lower primary progression rate (~15% vs. 35%), a superior overall response rate (over 30% vs. ~20%), and a more durable pharmacodynamic effect. This differentiation underpins a strategic Phase III program in renal cell carcinoma (RCC) designed to outmaneuver Merck; the PEAK-1 trial combines casdatifan with the widely used TKI cabozantinib, a design described as cleaner than Merck's trial, while the eVOLVE study with AstraZeneca (AZN) pioneers a TKI-sparing regimen in the frontline setting. Beyond casdatifan, the company anticipates near-term catalysts including overall survival (OS) data from its EDGE-Gastric study at ESMO for its anti-TIGIT antibody, dom-zim. Management argues its Fc-silent design avoids the T-cell depletion issues that plagued failed Fc-enabled TIGITs, and positive OS data would significantly derisk the pivotal STAR-221 trial. Furthermore, its CD73 inhibitor, quemli, has completed enrollment for its Phase III pancreatic cancer study 14 months ahead of schedule, accelerating a potential data readout to within the next 12-18 months.

Key Decisions for Investors

• Investors should focus on the October 6th investor event as a critical near-term catalyst, where the first progression-free survival (PFS) data for casdatifan will be presented, which is essential for validating its claimed best-in-class profile against Merck's belzutifan.
• The upcoming overall survival data from the EDGE-Gastric study at ESMO represents a significant derisking event; a positive outcome could reignite interest in the anti-TIGIT class and improve the perceived probability of success for the large STAR-221 and STAR-121 Phase III studies.
• The rapid enrollment of the Phase III trial for quemli in pancreatic cancer has accelerated a key binary event, and potential positive data within 12-18 months could provide significant upside not currently central to the primary investment thesis.
• Evaluate Arcus's differentiated clinical strategy in RCC, as the TKI-sparing first-line approach with AstraZeneca and the 'cleaner' second-line trial design represent potential long-term commercial advantages over Merck's development plan.